SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that Charles Baltic, Managing Director and Co-Head of Healthcare at Needham & Company, has been appointed to its board of directors. The appointment of Mr. Baltic increases the number of board members to six and the number of independent directors to five.
"On behalf of the entire board and management team, I am delighted to welcome Charles to Marshall Edwards," said Professor Bryan R.G. Williams, Chairman of the board of directors. "Charles' healthcare investment banking experience spans a broad range of equity, structured, convertible and debt financings in both the public and private markets, as well as numerous M&A and advisory assignments. His firsthand knowledge of the capital markets will be a valuable asset to the company as we continue to advance our drug candidates along the clinical development path."
Mr. Baltic has more than 19 years of experience working with life science and healthcare companies in a significant variety of transactional contexts. During that time he has been involved in raising more than $7 billion in life science financings. Prior to joining Needham in 2009, Mr. Baltic was a Managing Director and head of the biotechnology practice at CRT Capital Group. Previously, he served as a Managing Director in Healthcare Investment Banking at Wachovia Securities, where he founded and headed its biotechnology practice. Prior to that, he was with Healthcare Investment Banking at Cowen and Company for six years, ultimately serving as a Director in life sciences.
Prior to beginning his investment banking career in 1996, Mr. Baltic practiced corporate and securities law with Dewey Ballantine, representing numerous healthcare and securities
|SOURCE Marshall Edwards, Inc.|
Copyright©2010 PR Newswire.
All rights reserved